Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2010
10/20/2010EP2241351A1 Pharmaceutical composition comprising glycerol, white soft paraffin and liquid paraffin for the treatment of uremic xerosis
10/20/2010EP2241334A1 Method for determination of sensitivity to anti-cancer agent
10/20/2010EP2241333A1 Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
10/20/2010EP2241332A1 Therapeutic agent for pruritus
10/20/2010EP2241331A2 Novel anti-DC-SIGN antibodies
10/20/2010EP2241319A1 Combination of brimonidine and timolol for topical ophthalmic use
10/20/2010EP2241317A1 Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response
10/20/2010EP2241315A1 Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases
10/20/2010EP2240194A1 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
10/20/2010EP2240155A2 Devices, formulations, and methods for delivery of multiple beneficial agents
10/20/2010EP1866415B1 A cysteine-containing peptide tag for site-specific conjugation of proteins
10/20/2010EP1747778B1 Anti-fatigue composition
10/20/2010EP1594491B1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
10/20/2010EP1414496B1 Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride
10/20/2010EP1412484B1 Use of lysyl oxidase inhibitors for cell culture and tissue engineering
10/20/2010EP1360508B1 Prediction of wound healing by urinary nitrate assay
10/20/2010CN101868251A Pharmaceutical containing HIF-1alpha alpha and HIF-2alpha alpha expression inhibitor
10/20/2010CN101868235A Compositions and methods for inhibiting the activation of dsRNA-dependent protein kinase and tumor growth inhibition
10/20/2010CN101868231A Novel use of omega-3-fatty acid(s)
10/20/2010CN101868223A Water-containing composition which can be used as external composition
10/20/2010CN101862459A Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
10/20/2010CN101862456A Remedy
10/20/2010CN101862453A New self emulsifying drug delivery system
10/20/2010CN101862317A Pregabalin derivatives for the treatment of fibromyalgia and other disorders
10/20/2010CN101862306A New type slightly soluble oral medicine self-emulsification preparation and preparation method thereof
10/20/2010CN101862295A Aggregate having enhanced deformability and including at least three amphipatic substances
10/19/2010US7816560 N-nonyl-1,5,6-trideoxy-1,5-imino-D-galactitol; N-(7-oxa-nonyl)-1,5,6-trideoxy-1,5-imino-D-galactito; viricide; for treating hepatitis
10/19/2010US7816516 Reacting hydroxyalkyl starch (HAS) with the bioactive agent in a medium that includes water; drug-HAS conjugates for treating tumors, arrythmia, infectious diseases; bioavailability; nontoxic solvents; biodrug activity is not inactivated
10/19/2010US7816499 Antibody that binds histone deacetylase; transcription repressor activity and deacetylate cellular substrates; treatment of cell proliferation disease
10/19/2010US7816403 Administering a thiuram disulfide and a heavy metal ion; activated transcription factor/adenosine cyclic phosphate response element binding protein (atf/creb)
10/19/2010US7816384 Method for treating a demyelinating condition
10/19/2010US7816374 Administering to respiratory system an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof; chronic obstructive pulmonary disease
10/19/2010US7816363 Inhibitors of histone deacetylase
10/19/2010US7816342 Anti-obesity compositions
10/19/2010US7816322 Stabilizing dystrophin associated protein complexes on cell surfaces; utilizing polypeptide related to amino acids 38-365 of sequence 9; muscular dystrophies; neuromuscular and neurological disorders
10/19/2010US7816319 Methods and products for manipulating uncoupling protein expression
10/19/2010US7816075 treating a human afflicted with condition characterized by elevated serum triglyceride or very low density lipoprotein (VLDL), comprising the step of administering an inhibitor of human delta-9 stearoyl-CoA desaturase (SCD1) activity; coronary artery disease, Type II diabetes, obesity
10/19/2010US7815943 Blood flow enhancer and inflamation reducer, anticholesterol agents and oxidation reduction
10/19/2010US7815938 Film coating
10/19/2010US7815937 Liquiflash particles and an excipient mass; friability of less than 1%; need for conventional super disintegrant and having a friability of less than 1%; no need for conventional superdisintegrant
10/19/2010US7815921 Using patient's leukocyte concentration after incubation with colony stimulation factor as evaluative tool in predicting susceptibility to infection, bone marrow and autoimmune diseases after chemotherapeutic treatments
10/19/2010US7815914 methods of identifying susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling; provides for reovirus treatment of mammals to treat proliferative disorders including breast tumors, a subset of tumors in which mutation of ras gene is not believed to play significant role
10/19/2010US7815912 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
10/19/2010US7815911 Compositions and methods for treating Yersinia pestis infection
10/19/2010US7815909 human tumor necrosis factor alpha (TNF) inhibitors; for rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis
10/19/2010US7815907 Antibodies to insulin-like growth factor I receptor
10/19/2010CA2525245C Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
10/19/2010CA2464491C Conditioning solution for contact lenses
10/19/2010CA2458853C Use of fucans in the treatment of adhesions, arthritis and psoriasis
10/19/2010CA2456547C Process for preparing inhalable powders
10/19/2010CA2437196C A composition for the treatment of heart failure comprising levosimendan and a calcium ion source and/or an intreacellular calcium increasing agent
10/19/2010CA2429496C Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
10/19/2010CA2420159C Model animal for type iii allergy inflammation
10/19/2010CA2417629C Derivatives of variolin b
10/19/2010CA2416512C Enhancement of the action of anti-infective agents
10/19/2010CA2415577C Use of cox-2 inhibitors for preventing immunodeficiency
10/19/2010CA2400650C Compositions for preventing and treating digestive diseases
10/19/2010CA2399840C Use of roflumilast or pumafentrine in combination with methotrexate for the treatment of arthritic diseases
10/19/2010CA2399434C Isolation and transplantation of retinal stem cells
10/14/2010WO2010118390A1 Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
10/14/2010WO2010117936A1 Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
10/14/2010WO2010116899A1 Phosphorylation-inhibiting agent or dephosphorylating agent for pten
10/14/2010WO2010116673A1 Mitochondrial function-improving agent
10/14/2010WO2010116267A1 High dosage doramectin formulation
10/14/2010WO2010115932A1 Combination for the treatment of bone loss
10/14/2010WO2010115741A2 New therapeutic approaches for treating neuroinflammatory conditions
10/14/2010WO2010020799A3 Compositions for the treatment of neoplastic diseases
10/14/2010WO2009114098A8 Methods of treating hyperacidic disorders
10/14/2010US20100261746 Pharmaceutical formulation
10/14/2010US20100261745 Pharmaceutical formulation
10/14/2010US20100261744 Pharmaceutical formulation
10/14/2010US20100261726 Treatment of aml
10/14/2010US20100261670 Complexes of phosphate derivatives
10/14/2010US20100261273 Mammalian Receptor Proteins; Related Reagents and Methods
10/14/2010US20100260776 Therapeutic method for reducing angiogenesis
10/14/2010US20100260719 Methods for treatment of hepatocellular carcinoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
10/14/2010DE102009016719A1 Composition, useful as pharmaceutical preparation for e.g. prophylaxis of lipid metabolic disorders in humans and animals and treating atherosclerosis, comprises 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor and solid material
10/14/2010CA2758300A1 Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
10/14/2010CA2750626A1 High dosage doramectin formulation
10/13/2010EP2239674A1 Method for classifying and treating physiologic brain imbalances using quantitative EEG
10/13/2010EP2239270A2 Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction
10/13/2010EP2239269A1 Use of peptides derived from copolymer-1 as molecular weight markers
10/13/2010EP2239264A1 Antitumor agent
10/13/2010EP2239012A2 Pharmaceutical use of substituted amides
10/13/2010EP2238987A1 Sugar chain-related gene and use thereof
10/13/2010EP2237684A2 Agonists for antimicrobial peptide systems
10/13/2010EP1458734B1 Derivatives of isoindigo, indigo and indirubin and use in treating cancer
10/13/2010EP1255553B1 Use of trilostane or keto-trilostane in combination with an antioestrogen in the treatment of a hormone-dependent condition.
10/13/2010CN201602811U 多功能缝线 Multifunction sutures
10/13/2010CN101861155A Electricity-generating particulates and the use thereof
10/13/2010CN101861151A Cancer combination therapy with a selective inhibitor of histone deacetylase HDAC1, HDAC2 and/or HDAC3 and a microtubule stabilizer
10/13/2010CN101856498A Anti-septic shock medicine compound and application thereof
10/13/2010CN101856403A Medicinal composition, preparation method thereof and pharmaceutical application
10/13/2010CN101171038B The use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy
10/12/2010US7812058 Use of apogossypol derivatives to treat cancer; drug screening for Bcl-2 protein inhibitors
10/12/2010US7812044 Hormone sensitive vcancer; antiproliferative agents ; induction apoptosis; angiotensin inhibitors
10/12/2010US7812009 Mastitis treatment
10/12/2010US7812000 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
10/12/2010US7811992 Measuring binding of Bradykinin and angiogensin receptor; calibration; animal hibernation
10/12/2010US7811984 BV8 nucleic acids and polypeptides with mitogenic activity
1 ... 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 ... 1151